Search results
Study finds most patients in TARGET-NASH registry meet revised MASLD criteria
Pharmaceutical Technology via Yahoo Finance· 2 days agoIn 2023, MASLD replaced the umbrella term of nonalcoholic fatty liver disease (NAFLD) to avoid the...
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity...
Motley Fool via Yahoo Finance· 20 hours agoThe company is still relatively small, with a market cap of around $6 billion. Its experimental...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero...
Morningstar· 2 days agoFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO) and reminds investors ...
Madrigal Pharmaceuticals senior VP sells $570,000 in stock By Investing.com
Investing.com· 4 hours agoRecent filings with the Securities and Exchange Commission reveal that Robert E. Waltermire, Senior...
'Dramatic' Phase 2 Results for Survodutide in MASH, Fibrosis
Medscape· 3 days agoSurvodutide, a dual agonist that targets glucagon and glucagon-like peptide 1 receptors, led to a...
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 5 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
Cantor Fitzgerald Reiterates “Overweight” Rating for 89bio (NASDAQ:ETNB)
ETF DAILY NEWS· 1 day ago89bio (NASDAQ:ETNB – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued on Wednesday, Benzinga reports ...
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
Morningstar· 7 days agoThe efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on liver histology ...
Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To Triple
Investor's Business Daily· 3 days agoRevenue from Eli Lilly's weight-loss drug is expected to triple over the next five years to over $50...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero...
Morningstar· 2 days agoPomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO). Such investors are advised to contact Danielle ...